Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBXNF research report →
Price Chart
About the company
Operating internationally, with key markets spanning Canada, the United States, Germany, and the United Kingdom, IBEX Technologies Inc. focuses on the development and sale of enzymes for various biomedical purposes. Its extensive product catalog includes a range of recombinant glycosaminoglycan lyases, such as Heparinase I, II, and III, alongside Chondroitinase AC and B.
- CEO
- Paul Baehr
- IPO
- 2018
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on IBXNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $25.27M
- P/E
- 9.06
- PEG
- 0.04
- P/S
- 4.74
- P/B
- 2.64
- EV/EBITDA
- 18.53
- Div Yield
- 0.00%
- Gross Margin
- 69.41%
- Op Margin
- -19.76%
- Net Margin
- 51.97%
- ROE
- 33.34%
- ROIC
- -9.71%
Latest fiscal year · YoY change
- Revenue
- $7.49M-5.1%
- Gross Profit
- $5.20M-3.0%
- Op Income
- $-1,480,579
- Net Income
- $3.89M+132.5%
- EPS
- $0.16+137.4%
- OCF Growth
- -37.2%
- FCF Growth
- -63.9%
- Beta
- -0.04
- RSI (14)
- 64
No earnings-call transcripts are available for IBXNF yet.
- Free Float
- 61.4%
- Shares Outstanding
- 25.27M
- Float Shares
- 15.53M
Our IBXNF coverage
Recent articles, reports, and earnings notes.
No research on IBXNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBXNF report →